Reading SMTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SMTI free→Reading SMTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SMTI free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but earnings quality is fragile, reported profits aren't backed by cash. Management's recent track record has been fairly steady, and risk is elevated. The sector backdrop is a headwind, and compared with sector peers, SMTI is below typical. Peer multiples imply a price about 34% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak or earnings quality is fragile, historically a value-trap pattern. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 3 valuation methods, at three horizons. Current price $21.89. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $22 SMTI trades at 2× p/s, below its 3× p/s peer median. Our $34 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 36% below a flat-multiple fair value, below our forecast of about 18%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 0.15x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-0.07. 0 raised, 0 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$212.
How much price usually moves either way.
On a bad day, this stock has moved -$510.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,429.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Revenue growth is a key goal for Sanara. Strong growth signals success in their strategy.
Confirms:Q2 revenue growth exceeds 10% year over year.
Disproves:Q2 revenue growth falls below 5% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SMTI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Termination of a Material Definitive Agreement. As previously disclosed, on March 20, 2023, Sanara MedTech Inc. (the “Company”) entered into a Transaction Advisory Services Agreement (the “Services Agreement”) with The Catalyst Group, Inc., a Texas corporation (“Catalyst”), effective as of March 1, 2023. Pursuant to the Services Agreement, Catalyst agreed to perform certain transaction advisory, business and organizational strategy, finance, marketing, operational and strategic planning, rela…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SMTI Sanara Medtech, Inc. | Below typical Show detailsSector percentile: 24 of 100 | inexpensive | elevated |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 74 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 94 of 100 | fair | elevated |
6 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing revenue through strategic initiatives and market expansion.
Enhance operating income through cost management and efficiency improvements.
Focus on improving gross profit margins through strategic pricing and cost control.
Why it matters: Higher operating income means better control of costs. It also shows more efficiency.
Confirms:Operating income goes up by over 15% from Q1.
Disproves:Operating income goes down or stays the same from Q1.
Why it matters: New M&A activity may show changes in strategy or chances for growth.
Confirms one read:Announcement of a new M&A deal within the next quarter.
Confirms the other:No new M&A announcements or further terminations in the next quarter.
Results of Operations and Financial Condition. On May 11, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Secur…
Results of Operations and Financial Condition. On March 24, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 1…
Results of Operations and Financial Condition. On January 23, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fourth quarter and full year 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes o…
Results of Operations and Financial Condition. On November 11, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing that it has initiated a strategic realignment of its business, discontinuing operations of its Tissue Health Plus. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall n…